Literature DB >> 17047091

Angiotensinogen and transforming growth factor beta1: novel genes in the pathogenesis of Crohn's disease.

G E Hume, E V Fowler, D Lincoln, R Eri, D Templeton, T H Florin, J A Cavanaugh, G L Radford-Smith.   

Abstract

BACKGROUND: Angiotensin peptides may act locally as cytokines in several organ systems with elevated mucosal levels present in Crohn's disease. A variant in the angiotensinogen gene promoter results in increased peptide production, while transforming growth factor beta1 (TGFbeta1) codon 25 variants demonstrate variable peptide production, predisposing to fibrosis in several organs. AIMS: Conduct an Australian-based analysis of the angiotensinogen-6 variant in two independent inflammatory bowel disease (IBD) cohorts, and examine the role of angiotensinogen-6 and TGFbeta1 codon 25 variants in shaping Crohn's disease phenotype.
METHODS: IBD Patients (Crohn's disease = 347, ulcerative colitis = 147) and CD families (n = 148) from two cohorts, together with 185 healthy controls were genotyped for angiotensinogen-6. Genotype-phenotype analyses were performed for both angiotensinogen-6 and TGFbeta1 codon 25.
RESULTS: Angiotensinogen-6 AA genotype was significantly associated with Crohn's disease (p = 0.007, OR = 2.38, CI = 1.32-4.32) in cohort 1, but not in the smaller cohort 2 (p = 0.19). The association remained significant when the two cohorts were combined (p = 0.008), and in a TDT family analysis (p = 0.03). TGF 1 codon 25 was associated with stricturing Crohn's disease (p = 0.01, OR = 2.63, CI = 1.16-5.88) and a shorter time to intestinal resection (p = 0.06).
CONCLUSIONS: The association of the angiotensinogen-6 variant with Crohn's disease supports a potential role for angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in disease treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047091      PMCID: PMC2563170          DOI: 10.1136/jmg.2005.040477

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  33 in total

1.  Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors.

Authors:  Gunter Wolf; Ulrich Wenzel; Kevin D Burns; Raymond C Harris; Rolf A K Stahl; Friedrich Thaiss
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

2.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Authors:  J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice.

Authors:  Y Inokuchi; T Morohashi; I Kawana; Y Nagashima; M Kihara; S Umemura
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.

Authors:  Marta Ruiz-Ortega; Mónica Ruperez; Oscar Lorenzo; Vanesa Esteban; Julia Blanco; Sergio Mezzano; Jesus Egido
Journal:  Kidney Int Suppl       Date:  2002-12       Impact factor: 10.545

5.  Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats.

Authors:  Atsushi Kuno; Tamaki Yamada; Kazuhiko Masuda; Kumiko Ogawa; Mitsue Sogawa; Soichi Nakamura; Takahiro Nakazawa; Hirotaka Ohara; Tomoyuki Nomura; Takashi Joh; Tomoyuki Shirai; Makoto Itoh
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

6.  Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis.

Authors:  A El-Gamel; M R Awad; P S Hasleton; N A Yonan; J A Hutchinson; C S Campbell; A H Rahman; A K Deiraniya; P J Sinnott; I V Hutchinson
Journal:  J Heart Lung Transplant       Date:  1999-06       Impact factor: 10.247

7.  Host genetic factors influence disease progression in chronic hepatitis C.

Authors:  E E Powell; C J Edwards-Smith; J L Hay; A D Clouston; D H Crawford; C Shorthouse; D M Purdie; J R Jonsson
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

8.  TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease.

Authors:  E V Fowler; R Eri; G Hume; S Johnstone; N Pandeya; D Lincoln; D Templeton; G L Radford-Smith
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

Review 9.  Vascular inflammation: a role in vascular disease in hypertension?

Authors:  Agostino Virdis; Ernesto L Schiffrin
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-03       Impact factor: 2.894

10.  What Models of Granulomatous Inflammation Provide the Immunologist

Authors: 
Journal:  Methods       Date:  1996-04       Impact factor: 3.608

View more
  12 in total

1.  Phenotypic change and accumulation of smooth muscle cells in strictures in Crohn's disease: relevance to local angiotensin II system.

Authors:  Takehisa Suekane; Yoshihiro Ikura; Kenji Watanabe; Junko Arimoto; Yoko Iwasa; Yoshimi Sugama; Soichiro Kayo; Kenichi Sugioka; Takahiko Naruko; Kiyoshi Maeda; Kosei Hirakawa; Tetsuo Arakawa; Makiko Ueda
Journal:  J Gastroenterol       Date:  2010-04-02       Impact factor: 7.527

2.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

Review 3.  Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis.

Authors:  Shuvra Ray; Carlo De Salvo; Theresa T Pizarro
Journal:  Curr Opin Gastroenterol       Date:  2014-11       Impact factor: 3.287

4.  Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis.

Authors:  Manabu Okawada; Hiroyuki Koga; Scott D Larsen; Hollis D Showalter; Anjanette J Turbiak; Xiaohong Jin; Peter C Lucas; Elke Lipka; John Hillfinger; Jae Seung Kim; Daniel H Teitelbaum
Journal:  Dig Dis Sci       Date:  2011-03-12       Impact factor: 3.199

5.  An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis.

Authors:  Olga I Santiago; Edelmarie Rivera; Leon Ferder; Caroline B Appleyard
Journal:  Regul Pept       Date:  2007-10-23

6.  Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.

Authors:  Calen A Steiner; Jeffrey A Berinstein; Jeremy Louissaint; Peter D R Higgins; Jason R Spence; Carol Shannon; Cathy Lu; Ryan W Stidham; Joel G Fletcher; David H Bruining; Brian G Feagan; Vipul Jairath; Mark E Baker; Dominik Bettenworth; Florian Rieder
Journal:  Clin Gastroenterol Hepatol       Date:  2021-06-02       Impact factor: 11.382

Review 7.  Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review.

Authors:  Isabelle Cleynen; Peter Jüni; Geertruida E Bekkering; Eveline Nüesch; Camila T Mendes; Stefanie Schmied; Stefan Wyder; Eliane Kellen; Peter M Villiger; Paul Rutgeerts; Séverine Vermeire; Daniel Lottaz
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

8.  Polymorphisms of the cytokine genes TGFB1 and IL10 in a mixed-race population with Crohn's disease.

Authors:  Neogelia Pereira Almeida; Genoile Oliveira Santana; Tamara Celi Almeida; Maria Teresita Bendicho; Denise Carneiro Lemaire; Mauricio Cardeal; André Castro Lyra
Journal:  BMC Res Notes       Date:  2013-09-27

9.  The mRNA level of the transforming growth factor β1 gene, but not the amount of the gene product, can be considered as a potential prognostic parameter in inflammatory bowel diseases in children.

Authors:  Anna Liberek; Zbigniew Kmieć; Dorota Kartanowicz; Piotr M Wierzbicki; Marcin Stanisławowski; Lucyna Kaszubowska; Grażyna Luczak; Magdalena Góra-Gębka; Piotr Landowski; Agnieszka Szlagatys-Sidorkiewicz; Tomasz Liberek; Barbara Kamińska; Joanna Jakóbkiewicz-Banecka; Grzegorz Węgrzyn
Journal:  Int J Colorectal Dis       Date:  2012-05-15       Impact factor: 2.571

Review 10.  Hypoxia and Integrin-Mediated Epithelial Restitution during Mucosal Inflammation.

Authors:  Bridie J Goggins; Ciaran Chaney; Graham L Radford-Smith; Jay C Horvat; Simon Keely
Journal:  Front Immunol       Date:  2013-09-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.